Oppenheimer reiterated their hold rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a research note published on Monday.

A number of other research analysts have also weighed in on the company. BidaskClub upgraded Acceleron Pharma from a hold rating to a buy rating in a report on Wednesday, December 27th. HC Wainwright reaffirmed a buy rating and issued a $62.00 target price on shares of Acceleron Pharma in a research note on Monday, December 11th. Credit Suisse Group set a $51.00 target price on Acceleron Pharma and gave the stock a buy rating in a research note on Tuesday, November 14th. Royal Bank of Canada reaffirmed a hold rating on shares of Acceleron Pharma in a research note on Thursday, November 2nd. Finally, ValuEngine downgraded Acceleron Pharma from a hold rating to a sell rating in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $44.56.

Shares of Acceleron Pharma (XLRN) traded down $0.10 during mid-day trading on Monday, reaching $43.91. The company’s stock had a trading volume of 258,500 shares, compared to its average volume of 320,788. The stock has a market cap of $1,930.00, a price-to-earnings ratio of -17.02 and a beta of 1.59. Acceleron Pharma has a 12 month low of $23.07 and a 12 month high of $44.80.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.55) EPS. equities analysts expect that Acceleron Pharma will post -2.65 EPS for the current year.

In related news, EVP Matthew L. Sherman sold 4,633 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $42.71, for a total transaction of $197,875.43. Following the completion of the sale, the executive vice president now directly owns 77,700 shares of the company’s stock, valued at approximately $3,318,567. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Christopher Rovaldi sold 2,266 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $42.42, for a total value of $96,123.72. Following the sale, the senior vice president now directly owns 52,977 shares of the company’s stock, valued at $2,247,284.34. The disclosure for this sale can be found here. Insiders have sold a total of 135,021 shares of company stock valued at $5,034,598 over the last three months. Corporate insiders own 3.90% of the company’s stock.

Several large investors have recently modified their holdings of XLRN. Quantbot Technologies LP increased its position in shares of Acceleron Pharma by 416.3% during the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in Acceleron Pharma by 969.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 3,288 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in Acceleron Pharma in the 3rd quarter valued at about $225,000. PNC Financial Services Group Inc. grew its position in Acceleron Pharma by 57.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock valued at $258,000 after acquiring an additional 3,100 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Acceleron Pharma in the 3rd quarter valued at about $266,000. 85.70% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Acceleron Pharma (XLRN) Stock Rating Reaffirmed by Oppenheimer” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2018/01/12/acceleron-pharma-xlrn-stock-rating-reaffirmed-by-oppenheimer.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.